Ocugen Acquires Innovimmune Biotherapeutics for $15M
Ticker: OCGN · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1372299
| Field | Detail |
|---|---|
| Company | Ocugen, INC. (OCGN) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, rare-disease, pipeline-expansion
TL;DR
Ocugen buys Innovimmune for $15M to boost rare disease pipeline.
AI Summary
Ocugen, Inc. announced on May 31, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of Innovimmune Biotherapeutics, Inc. for an aggregate purchase price of $15 million. This acquisition is expected to strengthen Ocugen's rare disease pipeline.
Why It Matters
This acquisition aims to bolster Ocugen's portfolio in rare diseases, potentially leading to new treatment options and future revenue streams.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges and the uncertainty of the acquired company's pipeline success.
Key Numbers
- $15.0M — Acquisition Price (Aggregate purchase price for Innovimmune Biotherapeutics)
Key Players & Entities
- Ocugen, Inc. (company) — Registrant
- Innovimmune Biotherapeutics, Inc. (company) — Acquired company
- $15 million (dollar_amount) — Aggregate purchase price
- May 31, 2024 (date) — Effective date of agreement
FAQ
What is the primary strategic rationale behind Ocugen's acquisition of Innovimmune Biotherapeutics?
The acquisition is intended to strengthen Ocugen's rare disease pipeline.
What is the total purchase price for Innovimmune Biotherapeutics?
The aggregate purchase price is $15 million.
On what date was the definitive agreement for the acquisition signed?
The filing indicates the event date as May 31, 2024.
What type of company is Innovimmune Biotherapeutics?
Innovimmune Biotherapeutics is a company whose equity interests are being acquired by Ocugen, Inc., with the intent to bolster Ocugen's rare disease pipeline.
What is the expected impact of this acquisition on Ocugen's business?
The acquisition is expected to strengthen Ocugen's rare disease pipeline.
Filing Stats: 975 words · 4 min read · ~3 pages · Grade level 13.7 · Accepted 2024-06-06 16:31:02
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share OCGN The Nasdaq
Filing Documents
- tm2416569d1_8k.htm (8-K) — 31KB
- tm2416569d1_ex16-1.htm (EX-16.1) — 3KB
- 0001104659-24-069112.txt ( ) — 204KB
- ocgn-20240531.xsd (EX-101.SCH) — 3KB
- ocgn-20240531_lab.xml (EX-101.LAB) — 33KB
- ocgn-20240531_pre.xml (EX-101.PRE) — 22KB
- tm2416569d1_8k_htm.xml (XML) — 3KB
01. Changes in Registrant's Certifying
Item 4.01. Changes in Registrant's Certifying Accountant. Subsequent to filing of the Annual Report on Form 10-K for the year ended December 31, 2023 for Ocugen, Inc. (the "Company") and the Proxy Statement for the Company's Annual Stockholder Meeting, the Audit Committee ("Audit Committee") of the Board of Directors of the Company authorized management to initiate a strategic request-for-proposal process soliciting proposals from accounting firms to provide audit services to the Company as its independent registered public accounting firm for the fiscal year ending December 31, 2024. Management requested proposals from several independent registered public accounting firms, including Ernst & Young LLP ("EY"), the Company's current independent registered public accounting firm, in the process. On May 31, 2024, EY notified the Company of its decision to decline to participate in the request-for-proposal process and to decline to stand for re-election as the Company's independent registered public accounting firm for fiscal year 2024, which decision was not the result of any disagreement with the Company. EY will cease providing services following the filing of the Form 10-Q for the quarter ending June 30, 2024. The reports of EY on the Company's consolidated financial statements for the fiscal years ended December 31, 2023 and 2022 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that the audit reports of EY on the Company's consolidated financial statements as of and for the years ended December 31, 2023 and 2022 contained an explanatory paragraph which noted that the Company has suffered recurring losses from operations and there was substantial doubt as to the Company's ability to continue as a going concern, and the audit report of EY on the Company's consolidated financial statements as of and for the year ended December 31, 2023 contained an expl
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. The following exhibits are being furnished herewith: (d) Exhibits Exhibit No. Document 16.1 Letter from Ernst & Young LLP to the U.S. Securities and Exchange Commission, dated June 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 6, 2024 OCUGEN, INC. By: /s/ Shankar Musunuri Name: Shankar Musunuri Title: Chairman, Chief Executive Officer, & Co-Founder